FTC is working with Canadian and European enforcement agencies to come up with new approach to merger reviews that could look at effects on innovation and companies' past conduct. FTC to review closed mergers to see if corrective action is necessary, FTC acting chair says.
The US Federal Trade Commission may conduct stricter reviews of pharmaceutical mergers that consider the past behavior of the parties (such as price fixing and reverse payments), a merger’s impact on innovation, and new theories of competitive harm.
The FTC announced on 16 March that it has formed a new working group with competition enforcement agencies in Canada and Europe, the US Department of Justice, and offices of state attorneys general to
Patients from Asia saw a differential treatment effect versus non-Asian regions in the Phase III multiregional study, with an adverse survival trend seen in the latter group, the FDA said about the lymphoma drug.
Pink Sheet sister publication In Vivo spoke to the former FDA commissioner about the recent layoffs and their impact on vaccine and other product development.
European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.
